PUBLISHER: SkyQuest | PRODUCT CODE: 1259959
PUBLISHER: SkyQuest | PRODUCT CODE: 1259959
Global allergy immunotherapy market was valued to be USD 2.5 billion in 2021, and it is anticipated to reach USD 6.2 billion by 2028 at a CAGR of 9.2% over the forecast period (2022-2028).
According to the World Allergy Organization, 10-30% of the global population is currently affected by various types of allergies. Allergy occurs when the immune system of the body becomes abnormally sensitive to certain substances, such as a specific meal, pollen, fur, or dust. Food, dust, pollen, latex, medicines, and other allergens are examples of allergies. During allergy immunotherapy, the body is exposed to little levels of allergens in order to produce antibodies against them. Immunotherapy involves low-dose exposure to certain allergens on a frequent basis to help the body acclimatise to their presence, resulting in effective and rapid allergy treatment.
The expansion of industrialization and population, advancements in healthcare and medicine, and the introduction of new immunotherapeutic drugs are the key factors driving the global market for allergy immunotherapy. Recent regulatory approvals, such as those for oral dissolvable tablets, are being expanded in order to raise the worldwide allergy immunotherapy market share.
Top-down and bottom-up approaches were used to estimate and validate the size of global allergy immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.
Segments covered in this report:
The Global Allergy Immunotherapy Market is segmented based on treatment type, allergy type, distribution channel and region. Based on the Treatment Type, it is categorized into Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), and Oral Allergy Immunotherapy. Based on Allergy Type, it is categorized into Allergic Rhinitis, Asthma, Food Allergy, and Drug Allergy. Based on the Distribution Channel, it is categorized into Hospital Pharmacies, Retail Pharmacies and Drug Stores, and Online Pharmacies. Based on region, it is categorized into North America, Europe, Asia Pacific, The Middle East and Africa, and Latin America.
Drivers
Increasing allergy cases to help the allergy immunotherapy market grow: The increased prevalence of various allergies, as well as the development of novel sublingual immunotherapies in emerging countries, are the primary drivers of allergy immunotherapy market expansion. According to the American College of Allergy, Asthma, and Immunology, allergies are the sixth most frequent chronic ailment in the United States, costing more than USD 18 billion each year and affecting more than 50 million individuals. Food allergies are growing more widespread in both children and adults all around the world. As a result, the increased burden of allergic diseases is expected to boost demand for novel immunotherapies.
Restraints
Allergy immunotherapy, the most recent technology on the market, necessitates monthly maintenance. The cost of normal maintenance is relatively high due to the specific demand for professional workers in the process. As a result of this, the system's operational costs will climb. This is the primary cause or factor that is expected to severely impede the global allergy immunotherapy market. Furthermore, there is a need to increase awareness of this microgrid management system among many organizations, since this factor's ignorance of new technological developments may prove to be a barrier to the market's expansion for these systems.
Market Trends
High-resolution study of rare cells in local tissues has enabled the development of accurate and dependable biomarkers for allergy immunotherapy monitoring.
Aside from immunoglobulin and T-cell receptor transcript repertoires, genome-wide epigenetic changes provide a source of potential biomarkers for allergy immunotherapy monitoring.
Rare, antigen-specific immune cells can be counted and immuno-phenotyped using modern multiparameter flow and mass cytometry to track allergy immunotherapy.